Orally administered prolyl hydroxylase inhibitors are also effective for treating anemia and more convenient for outpatient treatment, but they have not demonstrated improved cardiovascular risks compared with erythropoietin and i.v. iron (4). Here, EPO is linked to anemia (phenotype).